Proteomics International to commercialise DKD test in China

Proteomics International has finalised agreement with major Chinese bio-pharmaceutical company New Summit Biopharma to commercialise its diabetic kidney diagnostic in China, in a deal potentially worth $312m annually.

Media release



  • This field is for validation purposes and should be left unchanged.